{
    "nctId": "NCT02262455",
    "briefTitle": "Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors",
    "officialTitle": "An Open-Label Multiple Ascending Dose Phase 1/1B Pharmacokinetic and Pharmacodynamic Study of STM 434, an Activin Type 2B Receptor Fc Fusion, Alone and in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Solid Tumors",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 32,
    "primaryOutcomeMeasure": "Maximum Tolerated Dose (MTD)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Males and postmenopausal females, 18 years or older\n* Advanced solid tumors with histologic diagnosis confirming cancer\n* Patients with recurrent metastatic or locally advanced disease considered refractory or intolerant to all standard treatment available for their tumor, or those tumors for which no standard treatment is available\n* Subjects with serous ovarian/fallopian tube/primary peritoneal, granulosa cell tumors or clear cell tumors considered platinum refractory/resistant, defined as having at least one prior platinum-based chemotherapeutic regimen with a subsequent platinum-free interval of \\< 12 months, having progression during platinum-based therapy, or having persistent disease after a platinum-based therapy, are eligible. Intolerant subjects, defined as unable to receive further platinum due to toxicity, are eligible.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Informed consent\n\nExclusion Criteria:\n\n* History of gastrointestinal bleeding within the past 6 months\n* History of epistaxis requiring medical/surgical intervention (such as nasal packing) within the past 6 months\n* History of central nervous system hemorrhage\n* History of bleeding diathesis or known qualitative platelet defect (including von Willebrand disease)\n* Ongoing need for therapeutic anticoagulants (full dose heparin, warfarin, factor Xa or direct thrombin inhibitors; rivaroxaban, apixaban, dabigatran) chronic use of aspirin or anti-platelet agents (ticlopidine or clopidogrel)\n* History of hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu syndrome)\n* Myocardial infarction, unstable angina within the past 6 months, or congestive heart failure New York Heart Association Class II or greater\n* Chemotherapy, hormonal therapy or radiation therapy within the past 3 weeks, antibody/biologic therapy within 5 half-lives or within the past 4 weeks (whichever is longer)\n* Current bowel obstruction\n* Brain metastasis\n* Known HIV infection and/or active Hepatitis B or C infection\n* Prior treatment with any investigational product within the past 4 weeks\n* Not willing to use contraception (inclusive of abstinence)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}